189 related articles for article (PubMed ID: 32675575)
1. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission.
Gunst JD; Højen JF; Søgaard OS
Curr Opin HIV AIDS; 2020 Sep; 15(5):309-315. PubMed ID: 32675575
[TBL] [Abstract][Full Text] [Related]
2. TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure.
Hvilsom CT; Søgaard OS
Front Immunol; 2021; 12():704617. PubMed ID: 34630386
[TBL] [Abstract][Full Text] [Related]
3. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
Hsu DC; Mellors JW; Vasan S
Front Immunol; 2021; 12():710044. PubMed ID: 34322136
[TBL] [Abstract][Full Text] [Related]
4. Vaccinal effect of HIV-1 antibody therapy: dream or reality?
Naranjo-Gomez M; Pelegrin M
Curr Opin HIV AIDS; 2023 Jul; 18(4):209-216. PubMed ID: 37144564
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies for HIV treatment and cure approaches.
Frattari GS; Caskey M; Søgaard OS
Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579
[TBL] [Abstract][Full Text] [Related]
6. Nanodepots Encapsulating a Latency Reversing Agent and Broadly Neutralizing Antibody Enhance Natural Killer Cell Cytotoxicity Against an in vitro Model of Latent HIV.
Ghofrani J; Bowen A; Chen J; Balakrishnan PB; Powell AB; Cherukula K; Cruz CRY; Jones RB; Lynch RM; Sweeney EE; Fernandes R
Int J Nanomedicine; 2023; 18():4055-4066. PubMed ID: 37520301
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Cohen YZ; Caskey M
Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
[TBL] [Abstract][Full Text] [Related]
8. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
9. Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?
Ananworanich J; McSteen B; Robb ML
Curr Opin HIV AIDS; 2015 May; 10(3):198-206. PubMed ID: 25700203
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
11. An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.
Tipoe T; Fidler S; Frater J
Curr Opin HIV AIDS; 2022 May; 17(3):162-170. PubMed ID: 35439790
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
13. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
[TBL] [Abstract][Full Text] [Related]
15. Next-generation bNAbs for HIV-1 cure strategies.
Schriek AI; Aldon YLT; van Gils MJ; de Taeye SW
Antiviral Res; 2024 Feb; 222():105788. PubMed ID: 38158130
[TBL] [Abstract][Full Text] [Related]
16. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
17. Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.
Thorlund K; Horwitz MS; Fife BT; Lester R; Cameron DW
BMC Infect Dis; 2017 Aug; 17(1):595. PubMed ID: 28851294
[TBL] [Abstract][Full Text] [Related]
18. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
19. Utilizing immunotherapy towards achieving a functional cure for HIV-1.
Sugiyama FHC; Dietz LL; Søgaard OS
Curr Opin HIV AIDS; 2024 Jul; 19(4):187-193. PubMed ID: 38686856
[TBL] [Abstract][Full Text] [Related]
20. Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.
Danesh A; Ren Y; Brad Jones R
Curr Opin HIV AIDS; 2020 Sep; 15(5):316-323. PubMed ID: 32732552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
